CO6331427A2 - Inhibodores de beta -lactamasa - Google Patents

Inhibodores de beta -lactamasa

Info

Publication number
CO6331427A2
CO6331427A2 CO10056779A CO10056779A CO6331427A2 CO 6331427 A2 CO6331427 A2 CO 6331427A2 CO 10056779 A CO10056779 A CO 10056779A CO 10056779 A CO10056779 A CO 10056779A CO 6331427 A2 CO6331427 A2 CO 6331427A2
Authority
CO
Colombia
Prior art keywords
beta
lactamasa
inhiboders
alpha
amino
Prior art date
Application number
CO10056779A
Other languages
English (en)
Inventor
Christopher John Burns
Randy W Jackson
Hongyu Xu
Rajesh Goswami
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6331427A2 publication Critical patent/CO6331427A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En la presente se dan a conocer ácidos alfa-amino-borónicos y sus derivados, los cuales actúan como inhibidores de beta-lactamasas. También, en la presente se dan a conocer composiciones farmacéuticas que comprenden ácidos alfa-amino-borónicos, y métodos de uso de las mismas.
CO10056779A 2007-11-13 2010-05-12 Inhibodores de beta -lactamasa CO6331427A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US279707P 2007-11-13 2007-11-13

Publications (1)

Publication Number Publication Date
CO6331427A2 true CO6331427A2 (es) 2011-10-20

Family

ID=40344560

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10056779A CO6331427A2 (es) 2007-11-13 2010-05-12 Inhibodores de beta -lactamasa

Country Status (21)

Country Link
US (2) US20100286092A1 (es)
EP (2) EP2220097A1 (es)
JP (2) JP2011503181A (es)
KR (2) KR20100109901A (es)
CN (2) CN101983203A (es)
AR (2) AR069463A1 (es)
AU (2) AU2008321444A1 (es)
BR (2) BRPI0820532A2 (es)
CA (2) CA2705393A1 (es)
CO (1) CO6331427A2 (es)
CR (1) CR11372A (es)
EA (2) EA201000774A1 (es)
EC (1) ECSP10010246A (es)
GT (1) GT201000143A (es)
IL (1) IL205205A0 (es)
MA (1) MA31874B1 (es)
MX (2) MX2010005250A (es)
TN (1) TN2010000203A1 (es)
TW (2) TW200936143A (es)
WO (2) WO2009064414A1 (es)
ZA (1) ZA201002467B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AR076667A1 (es) * 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
BR112013003045B1 (pt) 2010-08-10 2021-08-31 Rempex Pharmaceuticals, Inc. Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
CA2860142C (en) 2011-12-22 2020-10-27 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
MX2014008278A (es) 2012-01-06 2014-11-10 Univ South Florida Composiciones, metodos de uso y metodos de tratamiento.
AU2013237939A1 (en) * 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
RU2654692C2 (ru) * 2012-12-07 2018-05-22 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамаз
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104994844A (zh) * 2013-01-04 2015-10-21 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104981239B (zh) * 2013-01-04 2019-01-04 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
ES2730013T3 (es) 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
LT3604316T (lt) 2014-05-05 2024-02-26 Melinta Therapeutics, Inc. Boronato druskų sintezė
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
BR112016026291A2 (pt) * 2014-05-19 2017-08-15 Rempex Pharmaceuticals Inc Derivados do ácido borônico e usos terapêuticos dos mesmos
CN106687465B (zh) * 2014-06-11 2019-04-16 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20170024087A (ko) * 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
JP6835710B2 (ja) * 2014-10-01 2021-02-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ボロン酸誘導体
WO2016050359A1 (en) * 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
CA2963198A1 (en) * 2014-10-01 2016-04-07 Merck Patent Gmbh Boronic acid derivatives
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN107207537B (zh) 2014-12-19 2019-05-31 莱姆派克斯制药公司 用于生产硼酸衍生物的设备和连续流方法
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017222917A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Aliphatic prolinamide derivatives
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
IL268981B2 (en) 2017-03-06 2023-09-01 Venatorx Pharmaceuticals Inc Solid forms and combined preparations containing beta-lactamase inhibitor and uses thereof
EP3630782A4 (en) * 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019009369A1 (ja) * 2017-07-06 2019-01-10 大日本住友製薬株式会社 イミン誘導体
WO2019009370A1 (ja) * 2017-07-06 2019-01-10 大日本住友製薬株式会社 アミド誘導体
KR102626967B1 (ko) 2017-10-11 2024-01-18 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 이의 합성
CA3097127A1 (en) 2018-04-20 2019-10-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2020112542A1 (en) * 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor and uses thereof
CN110156820B (zh) * 2019-04-25 2021-06-25 四川大学 一类巯基酰胺硼酸类衍生物及其作为mbl和/或sbl抑制剂的用途
CN114340639A (zh) 2019-06-19 2022-04-12 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US7371729B2 (en) * 2002-09-09 2008-05-13 Trigen Limited Boronic acid salts useful in parenteral formulations
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
CA2528587A1 (en) * 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. .beta.-lactamase inhibitors and methods of use thereof
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
AR076667A1 (es) * 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa

Also Published As

Publication number Publication date
EA201000774A1 (ru) 2010-12-30
CR11372A (es) 2010-09-14
KR20100109901A (ko) 2010-10-11
ECSP10010246A (es) 2010-07-30
JP2011504468A (ja) 2011-02-10
CA2705393A1 (en) 2009-05-22
WO2009064414A1 (en) 2009-05-22
AU2008321444A1 (en) 2009-05-22
CN101983203A (zh) 2011-03-02
US20100286092A1 (en) 2010-11-11
ZA201002467B (en) 2011-02-23
BRPI0820532A2 (pt) 2012-07-10
WO2009064413A1 (en) 2009-05-22
TN2010000203A1 (en) 2011-11-11
TW200930707A (en) 2009-07-16
EP2220096A1 (en) 2010-08-25
IL205205A0 (en) 2010-12-30
CN101861324A (zh) 2010-10-13
EA201000775A1 (ru) 2010-12-30
MX2010005250A (es) 2010-11-05
BRPI0820531A2 (pt) 2012-07-10
JP2011503181A (ja) 2011-01-27
MA31874B1 (fr) 2010-11-01
AR069310A1 (es) 2010-01-13
MX2010005252A (es) 2011-04-11
GT201000143A (es) 2012-04-30
CA2705389A1 (en) 2009-05-22
AR069463A1 (es) 2010-01-27
EP2220097A1 (en) 2010-08-25
TW200936143A (en) 2009-09-01
US20100317621A1 (en) 2010-12-16
AU2008321443A1 (en) 2009-05-22
KR20100113485A (ko) 2010-10-21

Similar Documents

Publication Publication Date Title
CO6331427A2 (es) Inhibodores de beta -lactamasa
UY32626A (es) Inhibidores de beta-lactamasa
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CR10148A (es) Derivados de las benzamidas y heteroarenos
HN2006035237A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
CR20110216A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
CR20110135A (es) INHIBIDORES DE cMET
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
UY30796A1 (es) 3-h-pirazolopiridinas y sales de éstas, composiciones farmacéuticas que las comprenden, métodos para prepararlas, y sus usos
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP099721A (es) Inhibidores de cinasa p70 s6
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
HN2007000267A (es) Compuestos de 4-metil piridopirimidinoma
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
CR20110562A (es) Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
CR11826A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-

Legal Events

Date Code Title Description
FA Application withdrawn